title: Minimal residual disease-directed therapy in acute myeloid leukemia.
authors: Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany;
authors: Sabine
authors: S
authors: Kayser
authors: Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany;
authors: Richard F
authors: RF
authors: Schlenk
authors: Department of Medical and Molecular Genetics, King's College London, Faculty of Life Sciences and Medicine, London, United Kingdom;
authors: David
authors: D
authors: Grimwade
authors: Buffalo Medical Group, Buffalo, NY;
authors: Victor E D
authors: VE
authors: Yosuico
authors: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and Department of Medicine, Division of Hematology, and Department of Epidemiology, University of Washington, Seattle, WA.
authors: Roland B
authors: http://orcid.org/0000-0002-9268-3341
authors: RB
authors: Walter
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D050676:Core Binding Factor Alpha 2 Subunit / Q000235:genetics; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D008297:Male; D018365:Neoplasm, Residual / Q000175:diagnosis / Q000235:genetics / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D000075142:RUNX1 Translocation Partner 1 Protein
chemical_list: C107844:AML1-ETO fusion protein, human; D000970:Antineoplastic Agents; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; D000075142:RUNX1 Translocation Partner 1 Protein; D003561:Cytarabine; D015255:Idarubicin